Ingenol mebutate gel for actinic keratosis.

  title={Ingenol mebutate gel for actinic keratosis.},
  author={Mark G. Lebwohl and Neil A. Swanson and Lawrence Anderson and Anita E. Melgaard and Zhenyi Xu and Brian Berman},
  journal={The New England journal of medicine},
  volume={366 11},
BACKGROUND Actinic keratosis is a common precursor to sun-related squamous-cell carcinoma. Treating actinic keratoses and the surrounding skin area (i.e., field therapy) can eradicate clinical and subclinical actinic keratoses. Topical field therapy currently requires weeks or months of treatment. We investigated the efficacy and safety of a new topical field therapy for actinic keratosis, ingenol mebutate gel (0.015% for face and scalp and 0.05% for trunk and extremities). METHODS In four… 

Figures and Tables from this paper

Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects*
Ingenol mebutate is well-tolerated for the treatment of actinic keratosis, with good patient adherence thanks to the short treatment period, and the most common side effects were erythema, edema, desquamation, pruritus, and local erosion.
Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects
The study shows that ingenol mebutate is highly efficacious field treatment for actinic keratosis, a precancerous lesion leading to squamous cell carcinoma.
Clinical findings using ingenol mebutate gel to treat actinic keratoses.
Ingenol Mebutate for the Treatment of Actinic Keratosis
Topical ingenol mebutate gel, derived from the sap of the plant Euphorbia peplus, has been recently FDA-approved as a field therapy for treatment of AKs and its efficacy, safety, and tolerability have been demonstrated.
Erosive pustular dermatosis of the scalp following topical ingenol mebutate for actinic keratoses
The clinical features, laboratory data and history of treatment with ingenol mebutate were consistent with a diagnosis of erosive pustular dermatosis of the scalp (EPDS), and the clinical setting and its rapid resolution with treatment also supported the clinical diagnosis.
Treatment of Actinic Keratosis With Picato ® ( ingenol mebutate ) Gel
Although AK does not pose immediate health risks, these lesions, over time, are associated with progression to SCC, but it is impossible to accurately predict which AK lesions are mostly like to convert to cancer, so treatment of all AK lesions is recommended.
Impetigo After Actinic Keratosis Treatment With Ingenol Mebutate Gel: An Important Complication
A case of a patient who developed impetigo after applying ingenol mebutate gel for treatment of actinic keratosis, an alternative preferred by some dermatologists over lesion-directed modalities because the former allows for coverage of subclinical AKs.
Treatment of facial actinic keratoses with a cream containing octatrienoic acid: a multicenter clinical experience.
  • M. Lombardi, A. Rossi, C. Costa
  • Medicine
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • 2018
The results of the study allow the use of topical octatrienoic acid was effective and well tolerated for topical treatment of AKs leading to overall clinical improvement in approximately 90% of subjects treated for 60 days.


Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks.
Once-daily administration of 0.5% fluorouracil cream for 1, 2, or 4 weeks is safe and effective for the treatment of AKs, although efficacy increased with increasing treatment duration.
Development of a treatment algorithm for actinic keratoses: a European Consensus.
An algorithm designed to assist physicians with their treatment decisions, giving recommendations for both field directed and lesion directed treatment ofActinic keratoses is described, for the first time, a summary of European best practice recommendations for the treatment of AK.
Aloe vera was the most popular remedy and paw paw and creams such as lanolin were also popular despite their generally perceived lack of efficacy, and Euphorbia peplus was unanimously considered an effective treatment.
Topical treatment of actinic keratoses with 3·0% diclofenac in 2·5% hyaluronan gel
The development of an effective and well‐tolerated topical treatment for AK is desirable and this work contributes towards that goal.
A randomised study of topical 5% imiquimod vs. topical 5‐fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‐year follow‐up
Background  Actinic keratoses (AK) frequently occur on sun‐exposed skin and are considered as in situ squamous cell carcinoma. To date, no treatment algorithm exists for first or second line
Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death.
PEP005 emerges as a new topical anti-skin cancer agent that has a novel mode of action involving plasma membrane and mitochondrial disruption and primary necrosis, ultimately resulting in an excellent cosmetic outcome.
Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate1
Evidence that neutrophils are required to prevent relapse of skin tumors following topical treatment with a new anticancer agent, ingenol-3-angelate (PEP005), and a central role for neutrophil-mediated ADCC in preventing relapse are suggested, illustrating that neutophils can be induced to mediate important anticancer activity with specific chemotherapeutic agents.